Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2393
{ "count": 24756, "next": "http://api.gregory-ms.com/articles/?format=api&page=2394", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2392", "results": [ { "article_id": 843, "title": "Depression in multiple sclerosis: Is one approach for its management enough?", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 18;51:102904. doi: 10.1016/j.msard.2021.102904. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis (MS). Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide. Currently, there is no gold-standard, single treatment available for depression in MS. Pharmacotherapy, cognitive behavior therapy (CBT), and exercise training individually are moderately, yet incompletely, efficacious for managing depression in the general population and MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PURPOSE: This review provides an overview of evidence from meta-analyses and systematic reviews for current treatments of depression in persons with MS. This review further develops the rationale for using a combinatory treatment approach in persons with MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We performed a narrative review of meta-analyses and systematic reviews regarding the current state of evidence for the three most common treatments of depression in persons with MS (i.e., antidepressant medication, cognitive-behavior therapy, and exercise training). We provide a concise assessment of the overall effect of these treatments on depression in the general population and then persons with MS. We further note short-comings of research on these treatments for depression.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: There is no single, gold-standard treatment for depression in MS, and we proposed that combinatory treatments should be considered for the management of depression in MS. However, there is a paucity of evidence for the use of combinatory therapy on depression and its outcomes in persons with MS, and this supports direct examination of the feasibility and efficacy of such combinatory approaches for MDD in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780807/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780807</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102904\">10.1016/j.msard.2021.102904</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780807/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 151223, "given_name": "C. Danielle", "family_name": "Jones", "ORCID": "http://orcid.org/0000-0003-2000-8854", "country": null }, { "author_id": 247014, "given_name": "Robert", "family_name": "Motl", "ORCID": null, "country": null }, { "author_id": 163419, "given_name": "Brian M", "family_name": "Sandroff", "ORCID": "http://orcid.org/0000-0002-2013-7632", "country": "US" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Depression", "multiple sclerosis", "one approach", "its management" ], "doi": "10.1016/j.msard.2021.102904", "access": "restricted", "takeaways": " Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis . Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide .", "categories": [] }, { "article_id": 844, "title": "Comparative effectiveness of psychotherapy approaches on Death Anxiety in Multiple Sclerosis Patients. A pilot randomized controlled trial", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 19;51:102914. doi: 10.1016/j.msard.2021.102914. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Death anxiety (DA) in chronic diseases has occupied the human mind more than other diseases. Therefore, multiple sclerosis (MS) patients are more prone to DA due to recurrence periods.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Among the psychological interventions the two approaches of logotherapy (LT) and acceptance and commitment therapy (ACT), They pay more attention and concentration on the subject of suffering. Therefore, the present study aimed to compare the effectiveness of these two approaches on DA in MS patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The statistical population included 48 women who were diagnosed as MS patients and had medical records at Iran MS Society in Tehran, in terms of entry and exit criteria, which were selected by convenience sampling. Then they were randomly divided into two experimental groups and one control group. This plan has an independent variable at three levels including: LT, ACT and the control group. The dependent variables are the subjects' scores on the Death Attitude Profile-Revised (DAP-R) (Wong., Reker & Gesser, 1994). Therapeutic interventions included 12 sessions of 2 h per week. A 3-hour workshop was held for the control group. in which patients were provided with basic information about the psychological problems of MS, but no strategy was presented. In order to obtain the results, the analysis of covariance was used and in the follow-up study, repeated measures analysis of variance with an intergroup variable (mixed model) was used.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: It showed that both LT and ACT groups were able to be effective and reduce DA in comparison with the control group and such a positive effect on the improvement of DA was evident both in the post-test and follow-up stages. However, no significant differences were observed in comparing the effectiveness of the two intervention methods, so both methods were effective in reducing DA due to the nature of suffering.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Considering the effectiveness of LT and ACT in reducing DA in MS patients, the results of this study can be used in order to achieve therapeutic goals and reduce psychological problems in chronic diseases.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780806/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780806</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102914\">10.1016/j.msard.2021.102914</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780806/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 153336, "given_name": "Behnam", "family_name": "Lotfifar", "ORCID": "http://orcid.org/0000-0001-9958-3928", "country": null }, { "author_id": 153337, "given_name": "Ezatolah", "family_name": "Ghadampour", "ORCID": "http://orcid.org/0000-0003-3120-384X", "country": "IR" }, { "author_id": 153338, "given_name": "Nasrin", "family_name": "Bagheri", "ORCID": "http://orcid.org/0000-0002-5919-2591", "country": "IR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Comparative effectiveness", "psychotherapy approaches", "Death Anxiety", "Multiple Sclerosis Patients", "A pilot", "controlled trial" ], "doi": "10.1016/j.msard.2021.102914", "access": "restricted", "takeaways": " Logotherapy (LT) and acceptance and commitment therapy (ACT) pay more attention and concentration on the subject of suffering . Both methods were effective in reducing DA due to the nature of suffering, so both methods were .", "categories": [] }, { "article_id": 839, "title": "Data Sharing Goals for Nonprofit Funders of Clinical Trials", "summary": "<div><p>J Particip Med. 2021 Mar 29;13(1):e23011. doi: 10.2196/23011.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies as investigators merge data sets to conduct new analyses, reproduce published findings to raise standards for original research, and learn from the work of others to generate new research questions. Nonprofit funders, including disease advocacy and patient-focused organizations, play a pivotal role in the promotion and implementation of data sharing policies. Funders are uniquely positioned to promote and support a culture of data sharing by serving as trusted liaisons between potential research participants and investigators who wish to access these participants' networks for clinical trial recruitment. In short, nonprofit funders can drive policies and influence research culture. The purpose of this paper is to detail a set of aspirational goals and forward thinking, collaborative data sharing solutions for nonprofit funders to fold into existing funding policies. The goals of this paper convey the complexity of the opportunities and challenges facing nonprofit funders and the appropriate prioritization of data sharing within their organizations and may serve as a starting point for a data sharing toolkit for nonprofit funders of clinical trials to provide the clarity of mission and mechanisms to enforce the data sharing practices their communities already expect are happening.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779573/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779573</a> | DOI:<a href=\"https://doi.org/10.2196/23011\">10.2196/23011</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779573/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-28T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "JMIR Publications Inc.", "container_title": "Journal of Participatory Medicine", "authors": [ { "author_id": 152477, "given_name": "Timothy", "family_name": "Coetzee", "ORCID": "http://orcid.org/0000-0002-3031-7549", "country": null }, { "author_id": 223796, "given_name": "Mad\tPrice", "family_name": "Ball", "ORCID": "http://orcid.org/0000-0003-0544-5925", "country": null }, { "author_id": 223797, "given_name": "Marc", "family_name": "Boutin", "ORCID": "http://orcid.org/0000-0002-2304-8985", "country": null }, { "author_id": 223798, "given_name": "Abby", "family_name": "Bronson", "ORCID": "http://orcid.org/0000-0001-8127-182X", "country": null }, { "author_id": 223799, "given_name": "David T", "family_name": "Dexter", "ORCID": "http://orcid.org/0000-0002-7974-9588", "country": null }, { "author_id": 223800, "given_name": "Rebecca A", "family_name": "English", "ORCID": "http://orcid.org/0000-0002-4039-6105", "country": null }, { "author_id": 223801, "given_name": "Patricia", "family_name": "Furlong", "ORCID": "http://orcid.org/0000-0002-8307-3015", "country": null }, { "author_id": 223802, "given_name": "Andrew D", "family_name": "Goodman", "ORCID": "http://orcid.org/0000-0001-7642-4502", "country": null }, { "author_id": 223803, "given_name": "Cynthia", "family_name": "Grossman", "ORCID": "http://orcid.org/0000-0002-5849-6235", "country": null }, { "author_id": 223804, "given_name": "Adrian F", "family_name": "Hernandez", "ORCID": "http://orcid.org/0000-0003-3387-9616", "country": null }, { "author_id": 223805, "given_name": "Jennifer E", "family_name": "Hinners", "ORCID": "http://orcid.org/0000-0002-1188-9920", "country": null }, { "author_id": 223806, "given_name": "Lynn", "family_name": "Hudson", "ORCID": "http://orcid.org/0000-0002-1480-9463", "country": null }, { "author_id": 223807, "given_name": "Annie", "family_name": "Kennedy", "ORCID": "http://orcid.org/0000-0002-0987-675X", "country": null }, { "author_id": 223808, "given_name": "Mary Jane", "family_name": "Marchisotto", "ORCID": "http://orcid.org/0000-0002-9196-8329", "country": null }, { "author_id": 223809, "given_name": "Lynn", "family_name": "Matrisian", "ORCID": "http://orcid.org/0000-0002-5631-2826", "country": null }, { "author_id": 223810, "given_name": "Elizabeth", "family_name": "Myers", "ORCID": "http://orcid.org/0000-0003-4576-7320", "country": null }, { "author_id": 181262, "given_name": "W. Benjamin", "family_name": "Nowell", "ORCID": "http://orcid.org/0000-0002-4951-6476", "country": "US" }, { "author_id": 223811, "given_name": "Brian A", "family_name": "Nosek", "ORCID": "http://orcid.org/0000-0001-6797-5476", "country": null }, { "author_id": 223812, "given_name": "Todd", "family_name": "Sherer", "ORCID": "http://orcid.org/0000-0001-9667-6600", "country": null }, { "author_id": 223813, "given_name": "Carolyn", "family_name": "Shore", "ORCID": "http://orcid.org/0000-0002-5988-5128", "country": "US" }, { "author_id": 184656, "given_name": "Ida", "family_name": "Sim", "ORCID": "http://orcid.org/0000-0002-1045-8459", "country": "US" }, { "author_id": 223814, "given_name": "Luba", "family_name": "Smolensky", "ORCID": "http://orcid.org/0000-0002-3587-0941", "country": null }, { "author_id": 223815, "given_name": "Christopher", "family_name": "Williams", "ORCID": "http://orcid.org/0000-0002-2623-533X", "country": null }, { "author_id": 223816, "given_name": "Julie", "family_name": "Wood", "ORCID": "http://orcid.org/0000-0002-9506-1847", "country": null }, { "author_id": 199404, "given_name": "Sharon F", "family_name": "Terry", "ORCID": "http://orcid.org/0000-0002-0452-9329", "country": "US" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Data Sharing Goals", "Nonprofit Funders", "Clinical Trials" ], "doi": "10.2196/23011", "access": "open", "takeaways": " Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies . Nonprofit funders play a pivotal role in the promotion and implementation of data sharing policies .", "categories": [] }, { "article_id": 841, "title": "Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry", "summary": "<div><p>Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (<i>p</i> < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, <i>p</i> < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, <i>p</i> = 0.001).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779361/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779361</a> | DOI:<a href=\"https://doi.org/10.1177/13524585211003291\">10.1177/13524585211003291</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779361/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-12T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 184413, "given_name": "A", "family_name": "Theodorsdottir", "ORCID": "http://orcid.org/0000-0001-7894-611X", "country": null }, { "author_id": 247019, "given_name": "Birgit", "family_name": "Debrabant", "ORCID": null, "country": null }, { "author_id": 167429, "given_name": "Melinda", "family_name": "Magyari", "ORCID": "http://orcid.org/0000-0002-0972-5222", "country": null }, { "author_id": 324613, "given_name": "Matthias", "family_name": "Kant", "ORCID": "http://orcid.org/0000-0001-5090-8234", "country": "DK" }, { "author_id": 240415, "given_name": "Peter V", "family_name": "Rasmussen", "ORCID": null, "country": null }, { "author_id": 247021, "given_name": "Carl-Fredrik", "family_name": "Malmberg", "ORCID": null, "country": null }, { "author_id": 247022, "given_name": "Iver A", "family_name": "Norberg", "ORCID": null, "country": null }, { "author_id": 247023, "given_name": "Victoria", "family_name": "Hansen", "ORCID": null, "country": null }, { "author_id": 247024, "given_name": "Danny", "family_name": "Bech", "ORCID": null, "country": null }, { "author_id": 247025, "given_name": "Mathias F", "family_name": "Schmidt", "ORCID": null, "country": null }, { "author_id": 247026, "given_name": "Karen", "family_name": "Schreiber", "ORCID": null, "country": null }, { "author_id": 247027, "given_name": "Jette L", "family_name": "Frederiksen", "ORCID": null, "country": null }, { "author_id": 160395, "given_name": "Finn", "family_name": "Sellebjerg", "ORCID": "http://orcid.org/0000-0002-1333-9623", "country": null }, { "author_id": 163649, "given_name": "Zsolt", "family_name": "Illes", "ORCID": "http://orcid.org/0000-0001-9655-0450", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Alemtuzumab treatment", "Denmark", "A national study", "the Danish Multiple Sclerosis Registry" ], "doi": "10.1177/13524585211003291", "access": "restricted", "takeaways": " After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab . Annual number of relapses was reduced by 69% in year 4 compared with the year prior . The Expanded Disability Status Scale (EDSS) score remained stable or improved . Novel serious serious AEs were not observed .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 118 } ] }, { "article_id": 837, "title": "Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial", "summary": "<div><p>JAMA Neurol. 2021 Mar 29. doi: 10.1001/jamaneurol.2021.0405. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">IMPORTANCE: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5.5, and recent clinical or magnetic resonance imaging disease activity.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1P1 modulators and a follow-up period of 30 days.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">MAIN OUTCOMES AND MEASURES: The primary end point was the annualized relapse rate. The secondary end points were the changes in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, the number of combined unique active lesions per year on magnetic resonance imaging, and time to 12-week and 24-week confirmed disability accumulation. Safety and tolerability were assessed. Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [64.9%]), the relative rate reduction for ponesimod vs teriflunomide in the annualized relapse rate was 30.5% (0.202 vs 0.290; P < .001); the mean difference in FSIQ-RMS, -3.57 (-0.01 vs 3.56; P < .001); the relative risk reduction in combined unique active lesions per year, 56% (1.405 vs 3.164; P < .001); and the reduction in time to 12-week and 24-week confirmed disability accumulation risk estimates, 17% (10.1% vs 12.4%; P = .29) and 16% (8.1% vs 9.9; P = .37), respectively. Brain volume loss at week 108 was lower by 0.34% (-0.91% vs -1.25%; P < .001); the odds ratio for NEDA-3 achievement was 1.70 (25.0% vs 16.4%; P < .001). Incidence of treatment-emergent adverse events (502 of 565 [88.8%] vs 499 of 566 [88.2%]) and serious treatment-emergent adverse events (49 [8.7%] vs 46 [8.1%]) was similar for both groups. Treatment discontinuations because of adverse events was more common in the ponesimod group (49 of 565 [8.7%] vs 34 of 566 [6.0%]).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS AND RELEVANCE: In this study, ponesimod was superior to teriflunomide on annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status, but not confirmed disability accumulation. The safety profile was in line with the previous safety observations with ponesimod and the known profile of other S1P receptor modulators.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02425644.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779698/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779698</a> | DOI:<a href=\"https://doi.org/10.1001/jamaneurol.2021.0405\">10.1001/jamaneurol.2021.0405</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779698/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-04-30T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "American Medical Association (AMA)", "container_title": "JAMA Neurology", "authors": [ { "author_id": 147953, "given_name": "Ludwig", "family_name": "Kappos", "ORCID": "http://orcid.org/0000-0003-4175-5509", "country": null }, { "author_id": 245326, "given_name": "Robert J.", "family_name": "Fox", "ORCID": null, "country": null }, { "author_id": 170157, "given_name": "Michel", "family_name": "Burcklen", "ORCID": "http://orcid.org/0000-0002-9459-3200", "country": null }, { "author_id": 172292, "given_name": "Mark S.", "family_name": "Freedman", "ORCID": "http://orcid.org/0000-0002-5932-9527", "country": "SA" }, { "author_id": 246970, "given_name": "Eva K.", "family_name": "Havrdová", "ORCID": null, "country": null }, { "author_id": 246972, "given_name": "Brian", "family_name": "Hennessy", "ORCID": null, "country": null }, { "author_id": 208605, "given_name": "Reinhard", "family_name": "Hohlfeld", "ORCID": "http://orcid.org/0000-0002-6302-1488", "country": null }, { "author_id": 246974, "given_name": "Fred", "family_name": "Lublin", "ORCID": null, "country": null }, { "author_id": 154801, "given_name": "Xavier", "family_name": "Montalban", "ORCID": "http://orcid.org/0000-0002-0098-9918", "country": "ES" }, { "author_id": 150619, "given_name": "Carlo", "family_name": "Pozzilli", "ORCID": "http://orcid.org/0000-0002-6360-4798", "country": null }, { "author_id": 170156, "given_name": "Tatiana", "family_name": "Scherz", "ORCID": "http://orcid.org/0000-0003-4262-7293", "country": null }, { "author_id": 246975, "given_name": "Daniele", "family_name": "D'Ambrosio", "ORCID": null, "country": null }, { "author_id": 246976, "given_name": "Philippe", "family_name": "Linscheid", "ORCID": null, "country": null }, { "author_id": 246977, "given_name": "Andrea", "family_name": "Vaclavkova", "ORCID": null, "country": null }, { "author_id": 246978, "given_name": "Magdalena", "family_name": "Pirozek-Lawniczek", "ORCID": null, "country": null }, { "author_id": 246979, "given_name": "Hilke", "family_name": "Kracker", "ORCID": null, "country": null }, { "author_id": 237093, "given_name": "Till", "family_name": "Sprenger", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Ponesimod", "Teriflunomide", "Patients", "Relapsing Multiple Sclerosis", "the Active-Comparator Phase", "OPTIMUM Study" ], "doi": "10.1001/jamaneurol.2021.0405", "access": "open", "takeaways": " The Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis . Brain volume loss at week 108 was lower by 0.34% (-0.91% vs -1.25%; P < .001)", "categories": [ { "category_id": 14, "category_description": "Aubagio is a medicine that contains the active substance teriflunomide. It is used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation destroys the protective sheath around the nerves. \r\n\r\nAubagio is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).", "category_name": "Aubagio", "category_slug": "aubagio", "category_terms": [ "teriflunomide", "aubagio" ], "article_count": 107 }, { "category_id": 32, "category_description": "Ponesimod", "category_name": "Ponesimod", "category_slug": "ponesimod", "category_terms": [ "ponesimod", "ponvory" ], "article_count": 21 } ] }, { "article_id": 838, "title": "MRI findings in blinded trials should be available to treating physicians - Yes", "summary": "<div><p>Mult Scler. 2021 Mar 29:1352458520984744. doi: 10.1177/1352458520984744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779365/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779365</a> | DOI:<a href=\"https://doi.org/10.1177/1352458520984744\">10.1177/1352458520984744</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779365/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 147248, "given_name": "Sandra", "family_name": "Vukusic", "ORCID": "http://orcid.org/0000-0001-7337-7122", "country": null }, { "author_id": 167428, "given_name": "Christine", "family_name": "Lebrun-Frénay", "ORCID": "http://orcid.org/0000-0002-3713-2416", "country": "FR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "MRI findings", "blinded trials", "physicians" ], "doi": "10.1177/1352458520984744", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 840, "title": "Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration", "summary": "<div><p>Acta Neuropathol. 2021 Mar 29. doi: 10.1007/s00401-021-02293-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients, thereby contributing significantly to clinical disability. However, the pathological mechanisms of meningeal inflammation-induced cortical pathology are still largely elusive. By extensive analysis of cortical microglia in post-mortem progressive MS tissue, we identified cortical areas with two MS-specific microglial populations, termed MS1 and MS2 cortex. The microglial population in MS1 cortex was characterized by a higher density and increased expression of the activation markers HLA class II and CD68, whereas microglia in MS2 cortex showed increased morphological complexity and loss of P2Y12 and TMEM119 expression. Interestingly, both populations associated with inflammation of the overlying meninges and were time-dependently replicated in an in vivo rat model for progressive MS-like chronic meningeal inflammation. In this recently developed animal model, cortical microglia at 1-month post-induction of experimental meningeal inflammation resembled microglia in MS1 cortex, and microglia at 2 months post-induction acquired a MS2-like phenotype. Furthermore, we observed that MS1 microglia in both MS cortex and the animal model were found closely apposing neuronal cell bodies and to mediate pre-synaptic displacement and phagocytosis, which coincided with a relative sparing of neurons. In contrast, microglia in MS2 cortex were not involved in these synaptic alterations, but instead associated with substantial neuronal loss. Taken together, our results show that in response to meningeal inflammation, microglia acquire two distinct phenotypes that differentially associate with neurodegeneration in the progressive MS cortex. Furthermore, our in vivo data suggests that microglia initially protect neurons from meningeal inflammation-induced cell death by removing pre-synapses from the neuronal soma, but eventually lose these protective properties contributing to neuronal loss.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779783/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779783</a> | DOI:<a href=\"https://doi.org/10.1007/s00401-021-02293-4\">10.1007/s00401-021-02293-4</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779783/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Acta Neuropathologica", "authors": [ { "author_id": 175989, "given_name": "Lynn", "family_name": "van Olst", "ORCID": "http://orcid.org/0000-0001-7569-0470", "country": null }, { "author_id": 175990, "given_name": "Carla", "family_name": "Rodriguez-Mogeda", "ORCID": "http://orcid.org/0000-0002-7849-9302", "country": null }, { "author_id": 295780, "given_name": "Carmen", "family_name": "Picon", "ORCID": null, "country": null }, { "author_id": 263914, "given_name": "Svenja", "family_name": "Kiljan", "ORCID": null, "country": null }, { "author_id": 295781, "given_name": "Rachel E.", "family_name": "James", "ORCID": null, "country": null }, { "author_id": 175991, "given_name": "Alwin", "family_name": "Kamermans", "ORCID": "http://orcid.org/0000-0002-3601-395X", "country": null }, { "author_id": 295782, "given_name": "Susanne M. A.", "family_name": "van der Pol", "ORCID": null, "country": null }, { "author_id": 295783, "given_name": "Lydian", "family_name": "Knoop", "ORCID": null, "country": null }, { "author_id": 273416, "given_name": "Iliana", "family_name": "Michailidou", "ORCID": null, "country": null }, { "author_id": 295784, "given_name": "Evelien", "family_name": "Drost", "ORCID": null, "country": null }, { "author_id": 295785, "given_name": "Marc", "family_name": "Franssen", "ORCID": null, "country": null }, { "author_id": 191536, "given_name": "Geert J.", "family_name": "Schenk", "ORCID": "http://orcid.org/0000-0002-9984-120X", "country": null }, { "author_id": 199658, "given_name": "Jeroen J. G.", "family_name": "Geurts", "ORCID": "http://orcid.org/0000-0002-4367-4641", "country": "CH" }, { "author_id": 197689, "given_name": "Sandra", "family_name": "Amor", "ORCID": "http://orcid.org/0000-0001-6169-9845", "country": null }, { "author_id": 295786, "given_name": "Nicholas D.", "family_name": "Mazarakis", "ORCID": null, "country": null }, { "author_id": 164525, "given_name": "Jack", "family_name": "van Horssen", "ORCID": "http://orcid.org/0000-0003-4078-7402", "country": null }, { "author_id": 254964, "given_name": "Helga E.", "family_name": "de Vries", "ORCID": null, "country": null }, { "author_id": 172132, "given_name": "Richard", "family_name": "Reynolds", "ORCID": "http://orcid.org/0000-0003-4622-4694", "country": "GB" }, { "author_id": 200460, "given_name": "Maarten E.", "family_name": "Witte", "ORCID": "http://orcid.org/0000-0002-1407-6220", "country": "NL" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Meningeal inflammation", "multiple sclerosis", "phenotypic changes", "cortical microglia", "that", "neurodegeneration" ], "doi": "10.1007/s00401-021-02293-4", "access": "open", "takeaways": " Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients . MS1 cortex was characterized by a higher density and increased expression of the activation markers HLA class II and CD68 . MS2 cortex showed increased morphological complexity and loss of P2Y12 and TMEM119 expression .", "categories": [] }, { "article_id": 835, "title": "Viscoelastic properties of white and gray matter-derived microglia differentiate upon treatment with lipopolysaccharide but not upon treatment with myelin", "summary": "Background: The biomechanical properties of the brain have increasingly been shown to relate to brain pathology in neurological diseases, including multiple sclerosis (MS). Inflammation and demyelination in MS induce significant changes in brain stiffness which can be linked to the relative abundance of glial cells in lesions. We hypothesize that the biomechanical, in addition to biochemical, properties of white (WM) and gray matter (GM)-derived microglia may contribute to the differential microglial phenotypes as seen in MS WM and GM lesions.MethodsPrimary glial cultures from WM or GM of rat adult brains were treated with either lipopolysaccharide (LPS), myelin, or myelin+LPS for 24 h or left untreated as a control. After treatment, microglial cells were indented using dynamic indentation to determine the storage and loss moduli reflecting cell elasticity and cell viscosity, respectively, and subsequently fixed for immunocytochemical analysis. In parallel, gene expression of inflammatory-related genes were measured using semi-quantitative RT-PCR. Finally, phagocytosis of myelin was determined as well as F-actin visualized to study the cytoskeletal changes.ResultsWM-derived microglia were significantly more elastic and more viscous than microglia derived from GM. This heterogeneity in microglia biomechanical properties was also apparent when treated with LPS when WM-derived microglia decreased cell elasticity and viscosity, and GM-derived microglia increased elasticity and viscosity. The increase in elasticity and viscosity observed in GM-derived microglia was accompanied by an increase in Tnfα mRNA and reorganization of F-actin which was absent in WM-derived microglia. In contrast, when treated with myelin, both WM- and GM-derived microglia phagocytose myelin decrease their elasticity and viscosity.ConclusionsIn demyelinating conditions, when myelin debris is phagocytized, as in MS lesions, it is likely that the observed differences in WM- versus GM-derived microglia biomechanics are mainly due to a difference in response to inflammation, rather than to the event of demyelination itself. Thus, the differential biomechanical properties of WM and GM microglia may add to their differential biochemical properties which depend on inflammation present in WM and GM lesions of MS patients.", "link": "https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-021-02134-x", "published_date": "2021-03-28T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Neuroinflammation", "authors": [ { "author_id": 201308, "given_name": "Thecla A.", "family_name": "Wageningen", "ORCID": "http://orcid.org/0000-0002-5304-9487", "country": null }, { "author_id": 305963, "given_name": "Nelda", "family_name": "Antonovaite", "ORCID": null, "country": null }, { "author_id": 305964, "given_name": "Erik", "family_name": "Paardekam", "ORCID": null, "country": null }, { "author_id": 290127, "given_name": "John J. P.", "family_name": "Brevé", "ORCID": null, "country": null }, { "author_id": 305965, "given_name": "Davide", "family_name": "Iannuzzi", "ORCID": null, "country": null }, { "author_id": 290129, "given_name": "Anne-Marie", "family_name": "van Dam", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-29T18:18:54Z", "noun_phrases": [ "Viscoelastic properties", "white and gray matter-derived microglia", "treatment", "lipopolysaccharide", "treatment", "myelin" ], "doi": "10.1186/s12974-021-02134-x", "access": "open", "takeaways": " Inflammation and demyelination in MS induce significant changes in brain stiffness which can be linked to the relative abundance of glial cells in lesions . We hypothesize that the biomechanical properties of white (WM) and gray matter (GM)-derived microglia may contribute to the differential microglial phenotypes as seen in MS WM and GM lesions .", "categories": [] }, { "article_id": 834, "title": "Prevalence and factors related to urinary incontinence in older adults women worldwide: a comprehensive systematic review and meta-analysis of observational studies", "summary": "Background: Urinary incontinence is a common condition in the general population and, in particular, the older adults population, which reduces the quality of life of these people, so this study aims to systematically examine and meta-analyse the overall prevalence of urinary incontinence in older women around the world and the related and influential factors.MethodsThis report is a comprehensive systematic review and meta-analysis of the findings of research on urinary incontinence in older adults people across the world through looking for MEDLINE, Cochrane Library Sciencedirect, Embase, Scopus, ProQuest and Persian databases, namely iranmedex, magiran, and SID from January 2000 to April 2020, the heterogeneity of the experiments was measured using the I2 index and the data processing was done in the Systematic Meta-Analysis programme.ResultsIn 29 studies and the sample size of 518,465 people in the age range of 55–106 years, urinary incontinence in older adults’ women in the world based on a meta-analysis of 37.1% (95% CI: 29.6–45.4%) was obtained. The highest prevalence of urinary incontinence was reported in older adults’ women in Asia with 45.1% (95% CI: 36.9–53.5%). Meta-regression also showed that with increasing the sample size and year of the study, the overall prevalence of urinary incontinence in the older adults women of the world decreased and increased, respectively, which were statistically significant differences (P < 0.05). According to studies, the most important factors influencing the incidence of urinary incontinence in older women are women’s age (p < 0.001), obesity (p < 0.001), diabetes (p < 0.001), women’s education (p < 0.001), delivery rank (p < 0.001), hypertension (p < 0.001), smoking (p < 0.001). They also have urinary tract infections (p < 0.001).ConclusionGiven the high prevalence of urinary incontinence in older women around the world, health policy makers must consider control and diagnostic measures in older women and prioritize treatment and rehabilitation activities.", "link": "https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-021-02135-8", "published_date": "2021-03-28T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Geriatrics", "authors": [ { "author_id": 246995, "given_name": "Sedighe", "family_name": "Batmani", "ORCID": null, "country": null }, { "author_id": 246996, "given_name": "Rostam", "family_name": "Jalali", "ORCID": null, "country": null }, { "author_id": 148106, "given_name": "Masoud", "family_name": "Mohammadi", "ORCID": "http://orcid.org/0000-0002-5722-8300", "country": "IR" }, { "author_id": 246997, "given_name": "Shadi", "family_name": "Bokaee", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-29T18:18:54Z", "noun_phrases": [ "Prevalence", "factors", "urinary incontinence", "older adults", "women", "a comprehensive systematic review", "meta-analysis", "observational studies" ], "doi": "10.1186/s12877-021-02135-8", "access": "open", "takeaways": " Urinary incontinence is a common condition in the general population and, in particular, the older adults population, which reduces the quality of life of these people . This study aims to systematically examine and meta-analyse the overall prevalence of urinary incontinent in older women around the world and the related and influential factors . The highest prevalence was reported in older adults’ women in Asia with 45.1% .", "categories": [] }, { "article_id": 836, "title": "A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases", "summary": "Background: Autoimmune rheumatic diseases (ARDs) are associated with a significant sex-bias, which becomes more evident post-puberty. This systematic review aims to elucidate the bidirectional relationship between puberty and ARD-related outcomes.MethodsStudies published in English until October 2019 were identified using a systematic search of endocrinology and rheumatology literature. Information was extracted on study design, sample size, demographics, puberty outcome measures, disease outcome measures, and main findings. The methodological quality of the studies included was analysed using the Newcastle-Ottawa Scale (NOS).ResultsSixteen non-randomised studies reporting on the impact of puberty on ARD outcomes (n = 7), ARD impact on puberty-related outcomes (n = 8), or both (n = 1) have been identified. The impact of puberty on ARD outcomes were investigated in patients with juvenile idiopathic arthritis (JIA)-associated uveitis (n = 1), juvenile systemic lupus erythematosus (JSLE) (n = 5) or in healthy controls who developed adult-onset SLE (n = 1) or had non-specific symptoms (n = 1). The impact of ARD on puberty outcomes was explored in JIA (n = 4) and JSLE (n = 3). Quality assessment of studies showed a small to moderate risk of bias overall (NOS 4–9/9). Due to large heterogeneity of the studies it was not possible to perform a meta-analysis. Multiple studies reported on delayed puberty in patients with JIA/JSLE, menstrual and hormonal abnormalities, and lower height and weight than controls. Earlier (pre-pubertal) onset of JSLE was correlated with more severe disease and more need for systemic treatment.ConclusionA bidirectional relationship exists between puberty and ARDs; however, more and better research is required to elucidate the complexity of this relationship. We propose puberty-related clinical assessments in patients with ARDs, which can improve patient outcomes and facilitate future research.", "link": "https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-021-00528-y", "published_date": "2021-03-28T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Pediatric Rheumatology", "authors": [ { "author_id": 282939, "given_name": "Nina M.", "family_name": "de Gruijter", "ORCID": null, "country": null }, { "author_id": 282942, "given_name": "Meena", "family_name": "Naja", "ORCID": null, "country": null }, { "author_id": 282943, "given_name": "Hannah", "family_name": "Peckham", "ORCID": null, "country": null }, { "author_id": 282945, "given_name": "Anna", "family_name": "Radziszewska", "ORCID": null, "country": null }, { "author_id": 282947, "given_name": "Matthew", "family_name": "Kinsella", "ORCID": null, "country": null }, { "author_id": 282948, "given_name": "James", "family_name": "Glenister", "ORCID": null, "country": null }, { "author_id": 282950, "given_name": "Elizabeth C.", "family_name": "Rosser", "ORCID": null, "country": null }, { "author_id": 282951, "given_name": "Gary E.", "family_name": "Butler", "ORCID": null, "country": null }, { "author_id": 252771, "given_name": "Elizabeth C.", "family_name": "Jury", "ORCID": null, "country": null }, { "author_id": 195905, "given_name": "Coziana", "family_name": "Ciurtin", "ORCID": "http://orcid.org/0000-0002-8911-4113", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-29T18:18:54Z", "noun_phrases": [ "A systematic review", "the bidirectional relationship", "puberty", "autoimmune rheumatic diseases" ], "doi": "10.1186/s12969-021-00528-y", "access": "open", "takeaways": " Autoimmune rheumatic diseases (ARDs) are associated with a significant sex-bias, which becomes more evident post-puberty . This systematic review aims to elucidate the bidirectional relationship between puberty and ARD-related outcomes .", "categories": [] } ] }